Showing results (61-70 of 119) with videos related to

Sort By:
Pageof 12
Gerontology|January 1, 1981
Arterial compliance, systolic pressure and heart rate in elderly women at rest and on exerciseC Sebban, P Berthaux, H Lenoir, et al.
Cancer Treatment Reports|June 1, 1987
Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trialE Archimbaud, D Fiere, D Treille-Ritouet, et al.
Neurophysiologie Clinique = Clinical Neurophysiology|November 25, 2010
The yield of routine EEG in geriatric patients: A prospective hospital-based studyV-H Nguyen Michel, Z Ourabah, Y Boudali, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemiaE Archimbaud, J Troncy, C Sebban, et al.
Leukemia|October 25, 2003
Adult lymphoblastic lymphoma: a retrospective analysis of 92 patients under 61 years included in the LNH87/93 trialsS Le Gouill, S Lepretre, J Brière, et al.
Presse Medicale (Paris, France : 1983)|May 18, 1985
[Severe quantitative bone marrow insufficiency: results of treatment with high-dose antilymphocyte serum]B Coiffier, H Vuvan, C Sebban, et al.
Hematology/Oncology Clinics of North America|January 9, 2001
Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87A Thiebaut, J P Vernant, L Degos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1995
Chemotherapy combined with zidovudine and GM-CSF in human immunodeficiency virus-related non-Hodgkin's lymphomaJ Gabarre, E Lepage, A Thyss, et al.
Blood|November 10, 1998
The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma GroupJ Blay, F Gomez, C Sebban, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 22, 2003
Clinical and pharmacokinetic phase II study of fotemustine in refractory and relapsing multiple myeloma patientsC Dumontet, J Jaubert, C Sebban, et al.
Pageof 12